Authors: Rudin, CM Holmlund, J Fleming, GF Mani, S Stadler, WM Schumm, P Monia, BP Johnston, JF Geary, R Yu, RZ Kwoh, TJ Dorr, FA Ratain, MJ

Citation: Cm. Rudin et al., Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer, CLIN CANC R, 7(5), 2001, pp. 1214-1220

Authors: Monia, BP Holmlund, J Dorr, FA

Citation: Bp. Monia et al., Antisense approaches for the treatment of cancer, CANCER INV, 18(7), 2000, pp. 635-650

Authors: O'Dwyer, PJ Stevenson, JP Gallagher, M Cassella, A Vasilevskaya, I Monia, BP Holmlund, J Dorr, FA Yao, KS

Citation: Pj. O'Dwyer et al., c-raf-1 depletion and tumor responses in patients treated with the c-raf-1antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A), CLIN CANC R, 5(12), 1999, pp. 3977-3982

Authors: Stevenson, JP Yao, KS Gallagher, M Friedland, D Mitchell, EP Cassella, A Monia, B Kwoh, TJ Yu, R Holmlund, J Dorr, FA O'Dwyer, PJ

Citation: Jp. Stevenson et al., Phase I clinical pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A), J CL ONCOL, 17(7), 1999, pp. 2227-2236